ARMP241115C5000
- 0.25
- 0.000.00%
Armata Pharmaceuticals Newsroom
Armata Pharmaceuticals Extends Credit Agreement and CMO Departs
Armata Pharmaceuticals | 10-Q: Quarterly report
Armata Pharmaceuticals Reports Q3 EPS (15c) Vs. (86c) Last Year
Express News | Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update
Armata Pharmaceuticals 3Q Loss/Shr 15c >ARMP
Armata Pharmaceuticals: Advancing Phage Therapy With Promising Clinical Progress and Investment Potential
Express News | Armata Pharmaceuticals Announces the Completion of Enrollment of Its Phase 1B/2a Disarm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus Aureus Bacteremia
Armata Pharmaceuticals Announces the Completion of Enrollment of Its Phase 1b/2a DiSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus Aureus Bacteremia
Armata Pharmaceuticals VP Richard Rychlik Departs With Benefits
Armata Pharmaceuticals (ARMP) Upgraded to Buy: What Does It Mean for the Stock?
Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Armata Pharmaceuticals Welcomes David House as New SVP of Finance
Express News | Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as Svp of Finance and Principal Financial Officer
Armata Pharmaceuticals GAAP EPS of -$0.25
Ladenburg Thalmann Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $9
Buy Rating Affirmed for Armata Pharmaceuticals Amid Positive Earnings and Promising Clinical Progress
Armata Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
Express News | Armata Pharmaceuticals Inc - Qtrly Shr Loss $0.25
Express News | Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update
Armata Pharmaceuticals 2Q Loss/Shr 25c >ARMP